Dr. Craig Seaman

Enrico M. Novelli, MD, is a classical (benign) hematologist, the Chief of the Section of Benign Hematology, and the medical director of the UPMC Adult Sickle Cell Disease Program. Board-certified in hematology, Dr. Novelli received his medical degree from the University of Milan, Italy. He completed his residency in internal medicine and fellowship in hematology-oncology at UPMC. Dr. Novelli specializes in sickle cell anemia and hemoglobinopathies. Dr. Novelli is highly rated in 9 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia.

Margaret Ragni is a Hematologist in Pittsburgh, Pennsylvania. Dr. Ragni is highly rated in 6 conditions, according to our data. Her top areas of expertise are Hemophilia A, Blood Clots, Von Willebrand Disease (VWD), Hemophilia B, and Hip Replacement.

Anwaar Saeed, MD, is an Associate Professor of Medicine and the Chief of the Gastrointestinal (GI) Medical Oncology Program at the University of Pittsburgh, University of Pittsburgh Medical Center (UPMC), and UPMC Hillman Cancer Center. She also serves as the Vice Chair of the Colorectal Cancer Committee of the NSABP Foundation. Her research efforts are focused on immune modulatory approaches in patients with gastric & esophageal cancer, colon cancer and hepatocellular carcinoma as well as chemoprevention/ immunoprevention in the high-risk GI population. She has published more than 150 peer reviewed papers, posters and book chapters, and have led more than 40 clinical trials, focused on various immune modulatory regimens including but not limited to immune checkpoint inhibitor combinations with chemotherapy, other checkpoint inhibitors, antibody drug conjugates, bi-specific T cell engagers (BiTE), angiogenesis inhibitors, as well as immunotherapy combinations with regional approaches like stereotactic radiosurgery and intensity-modulated radiation therapy. She currently leads several investigator-initiated trials focused on novel targeted immunotherapy combinations including the ongoing phase I/II CAMILLA multicohort study looking at Cabozantinib plus Durvalumab with or without Tremelimumab in GI malignancies. Results from phase I/II part of the CAMILLA led to the development of the currently ongoing global pivotal trial, STELLAR 303, in patients with previously treated microsatellite stable colorectal cancer. She is also the study chair for a soon to open SWOG/intergroup NCI national trial (S2303) testing a novel chemo-immunotherapy regimen in patients with advanced gastric & esophageal adenocarcinoma. Dr. Saeed is highly rated in 11 conditions, according to our data. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Stomach Cancer, Cataract Removal, and Gamma Knife Radiosurgery.